Ecologic® FEMI+ inside

Ecologic® FEMI+ is a multispecies designer probiotic medical device specifically developed to enhance the natural vaginal microbiota and thereby preventing the occurrence and/or recurrence of vaginal infections. The probiotic strains in Ecologic® FEMI+ have been selected for their capacity to (see figure 1):

  • inhibit growth of C. albicans (two different strains) and C. glabrata (level 1);
  • produce H2O2 (level 1);
  • possess hydrophobic characteristics as a parameter for adherence (level 1);
  • produce lactic acid as a parameter for metabolic activity (level 1).
Figure 1: Multispecies probiotics have multiple mechanisms that work at various levels.
Figure 1: Multispecies probiotics have multiple mechanisms that work at various levels. Ecologic® FEMI+ has been proven effective at level 1 and further testing is ongoing.

 

The selected strain combination from the Ecologic® Femi+ formulation:

  • Bifidobacterium bifidum   W28
  • Lactobacillus acidophilus  W70
  • Lactobacilus helveticus     W74
  • Lactobacillus plantarum    W21
  • Lactobacillus brevis           W63
  • Lactobacillus salivarius      W24

Probiotic formulation for reduction of recurrent candida infections

Worldwide, an estimated one billion women are affected by urogenital infections, including vaginal and urinary tract infections.

Vaginal infections caused by Candida species (candidiasis / yeast vaginitis) are a very common problem and frequently associated with improper use of vaginal medications, hormone replacement therapy, high-estrogen contraceptives, and other practices that change the vaginal microbiota.1 Common offending organisms in candidiasis are Candida albicans, though C. glabrata and other Candida species are increasingly identified. Antifungals and antimicrobials are frequently used as treatment options, however they can disrupt the vaginal microbiota’s balance even further.

C. albicans is a normal resident of the vagina but can overgrow and become pathogenic if the opportunity arises. Overgrowth of Candida and development of an infection is gene­rally associated with changes in the vaginal microbiota, estrogen production, and vaginal pH1. One frequent problem with Candida infections is that they have a high recurrence rate (60%). 2

Lactobacilli are the most prevalent microorganisms in a healthy vaginal microbiota.3 These lactobacilli play a major role in protec­ting the host against bacterial vaginosis and yeast vaginitis. Evidence suggests that there is an association between decreased vaginal lactobacilli and the development of vaginosis and vaginitis.4 Several mechanisms have been identified by which lactobacilli can help to prevent infections. Firstly, Lactobacillus spp. produce antimicrobial substances such as bacteriocins and hydrogen peroxide (H­2O2), which kill pathogens. Secondly, lactic acid produced by lactobacilli acidifies the vaginal environment and thereby prevents colonization and proliferation of potential pathogens. Thirdly, lactobacilli adhere and compete for adhesion sites in the vaginal epithelium, thereby inhibi­ting adhesion of pathogens.5 6

Figure 2: The microbial species that inhabit the vaginal tract play an important role in the maintenance of health and prevention of infections. The most common offender in candidiasis is C. albicans showing below.
Figure 2: The microbial species that inhabit the vaginal tract play an important role in the maintenance of health and prevention of infections. The most common offender in candidiasis is C. albicans showing below.

In vitro evidence

Since Candida is often the cause of a vaginal infection, the inhibition of two different C. albicans strains isolated from women with vaginal infections by Ecologic® FEMI+ was tested in vitro. C. albicans was co-cultured with or without (i.e. control) probiotic strains (108-109 colony forming units) at 37 °C. After 24 hours the growth of C. albicans was measured. The anti-Candida activity of each probiotic strain was measured as a decreased growth rate of C. albicans compared to the control (figure 3). The results show that all strains in Ecologic® FEMI+ are capable to inhibit C. albicans growth.

Figure 3: The anti-Candida activity of the probiotic bacteria measured as a decreased growth rate of C. albicans compared to the control.
Figure 3: The anti-Candida activity of the probiotic bacteria measured as a decreased growth rate of C. albicans compared to the control.

Medical device

Ecologic® FEMI+ is a medical device, containing a number of beneficial lactic acid producing bacteria, for topical vaginal application, which is intended to enhance the natural vaginal flora by preventing or alleviating any imbalance in this flora, thus inhibiting the growth of pathogens and thereby preventing the occurrence or recurrence of vaginal infec.tions such as vaginosis and vaginitis. It achieves this principally by promoting the formation of lactic acid, the production of hydrogen peroxide, and competition with potential pathogens for space and substrate.

Safety insurance

As the patient safety is key, the use of probiotics has been well researched in many different (incl. vulnerable) patient populations, including infants, elderly people and immunocompromised patients.
 

World Wide availability

The research formulations of Ecologic® are not sold as consumer products. However our worldwide business partners offer a selection of the formulations their own branded product(s). Thus the specific bacterial compositions can be found in different products around the world.

References

  • 1. Peters et al. Candida Vaginitis: When Opportunism Knocks, the Host Responds. PLoS Path. 2014;10(4).
  • 2. Reid, Bruce. Urogenital infections in women: can probiotics help? Postgrad Med J. 2003; 79: 428-432.
  • 3. Farage et al. Dynamics of the vaginal ecosystem-hormonal influences. Infect Dis Res Treat. 2010; 3: 1-15.
  • 4. Cribby et al. Vaginal microbiota and the use of probiotics. Interdiscip Perspect Infect Dis. 2008; 256490.
  • 5. Borges et al. The role of lactobacilli and probiotics in maintaining vaginal health. Arch Gynecol Obstet. 2013; DOI 10.1007/s00404-013-3064-9.
  • 6. Clinical studies with probiotics have shown good results in preventing and alleviating vaginal infections.Borges et al. The role of lactobacilli and probiotics in maintaining vaginal health. Arch Gynecol Obstet. 2013; DOI 10.1007/s00404-013-3064-9.

Formulation ingredients

Bacterial strains

  • Bifidobacterium bifidum W28
  • Lactobacillus acidophilus W70
  • Lactobacilus helveticus W74
  • Lactobacillus plantarum W21
  • Lactobacillus brevis W63
  • Lactobacillus salivarius W24

Ingredients

  • Microcrystalline cellulose
  • lactoferrin
  • magnesium stearate

Usage

Dosage 1 capsule
Daily CFU